



Year: 2017

Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials

Djalali, S ; Valeri, F ; Gerber, B ; Meli, D. N ; Senn, O

Abstract: **BACKGROUND:** In randomized controlled trials, non-vitamin K antagonist oral anticoagulants (NOACs) demonstrated noninferiority to vitamin K antagonists (VKAs) in patients who spent limited time in therapeutic range (TTR). In real-life patients, TTR is known to vary significantly across countries and health-care settings. **OBJECTIVE:** We aim to evaluate the quality of VKA treatment in Swiss primary care (PC) by comparing patients' median TTR to levels achieved in the phase III NOAC trials RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48. Patient characteristics affecting TTR control shall be estimated. **METHODS:** This is a retrospective longitudinal study in Swiss PC patients receiving VKA for 6 months. We identified patients from the PC research database FIRE (Family medicine International Classification of Primary Care Research using Electronic medical records) and calculated TTR according to Rosendaal formula. Comparative data from NOAC trials were retrieved from medical literature. Linear regression models were used to assess predictors of TTR. **RESULTS:** Primary care encounters of 215 patients were analyzed. Like in the NOAC trials, median observation period was 2.2 years, but patients were older (67.9% vs 38% 75 years) and differed in terms of concomitant diseases and drugs. Median TTR was 75% (65% in the NOAC trials). Female sex was independently associated with a lower TTR and significantly modified by increasing age. **CONCLUSION:** Practitioners should consider that patients in NOAC trials are only partly representative of PC patients, particularly in terms of TTR control. Only a minority of the observed patients would require a therapy switch to NOACs due to inadequate TTR. Further research is needed in order to identify specific features of care management that are associated with these outcomes.

DOI: <https://doi.org/10.1177/1076029616642514>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-124946>

Journal Article

Accepted Version

Originally published at:

Djalali, S; Valeri, F; Gerber, B; Meli, D. N; Senn, O (2017). Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. *Clinical and Applied Thrombosis/Hemostasis*, 23(6):685-695.

DOI: <https://doi.org/10.1177/1076029616642514>



Anticoagulation control in Swiss primary care: Time in therapeutic range percentages exceed benchmarks of phase III trials

Sima Djalali, MD^{1*}, Fabio Valeri¹, Bernhard Gerber, MD², Damian N. Meli, MD³, Oliver Senn, MD, MPH¹

¹ Institute of Primary Care, University of Zurich, University Hospital Zurich, Switzerland

² Department of Hematology, Istituto Oncologico della Svizzera Italiana, Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland

³ General Practice Center Huttwil, Huttwil, Switzerland

* Corresponding author:

Dr. med. Sima Djalali

Institute of Primary Care

University of Zurich, University Hospital Zurich

Pestalozzistrasse 24, 8091 Zurich, Switzerland

sima.djalali@usz.ch

E-Mail addresses of co-authors: fabio.valeri@usz.ch ; bernhard.gerber@eoc.ch ; d.meli@hin.ch ; oliver.senn@usz.ch

Word count: 3'499 (main text), 250 (abstract without headings)

Acknowledgements

This research received funding from the Swiss Academy of Medical Science (SAMS), Gottfried and Julia-Bangerter-Rhyner-Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would like to thank all participating GPs in the FIRE project.



Abstract

Background

In randomized controlled trials, novel oral anticoagulants (NOAC) demonstrated non-inferiority to Vitamin K antagonists (VKA) in patients who spent limited time in therapeutic range (TTR). In real-life patients TTR is known to vary significantly across countries and healthcare settings.

Objective

We aim to evaluate the quality of VKA treatment in Swiss primary care (PC) by comparing patients' median TTR to levels achieved in the phase III NOAC trials RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48. Patient characteristics affecting TTR control shall be estimated.

Methods

This is a retrospective longitudinal study in Swiss PC patients receiving VKA for ≥ 6 months. We identified patients from the PC research database «FIRE» and calculated TTR according to Rosendaal's formula. Comparative data from NOAC trials were retrieved from medical literature. Linear regression models were used to assess predictors of TTR.

Results

PC encounters of 215 patients were analyzed. Like in the NOAC trials, median observation period was 2.2 years, but patients were older (67.9% vs. 38% ≥ 75 years) and differed in terms of concomitant diseases and drugs. Median TTR was 75% (65% in the NOAC trials). Female sex was independently associated with a lower TTR and significantly modified by increasing age.

Conclusion



Practitioners should consider that patients in NOAC trials are only partly representative of PC patients, particularly in terms of TTR control. Only a minority of the observed patients would require a therapy switch to NOACs due to inadequate TTR. Further research is needed in order to identify specific features of care management that are associated with these outcomes.



Introduction

Optimal management of long-term anticoagulant treatment for the prevention and treatment of thrombosis, cardiovascular and cerebrovascular events is subject of increasing interest, mainly due to the availability of non-Vitamin K antagonist oral anticoagulants (NOACs). The introduction of NOACs questioned the usefulness of the Vitamin K antagonists (VKA), whose efficacy and safety are known to depend largely on the quality of anticoagulation control. Reports on patients' time spent in therapeutic range (TTR) of international normalized ratio (INR) level in daily practice of various countries suggest that the quality of anticoagulation control with VKA is poor, especially in primary care settings [1]. Reported TTR commonly ranges between 52% and 64%, but also lower values (29%) have been observed [2-24].

Specialized anticoagulation clinics (ACCs) and patients' self-monitoring tend to show better outcomes. However, in light of the high prevalence of patients in need of anticoagulant treatment, it does not seem feasible that solely ACCs could take care of these patients, and self-monitoring may not be feasible for everyone [15-22,25-29].

NOACs could represent a solution to this dilemma, since their pharmacologic properties simplify the administration and do not require monitoring [30]. However, the body of evidence in favor of NOACs is of questionable significance for the primary care setting since it is predominantly based on phase III randomized controlled trials (RCTs) with non-inferiority design and carefully selected patient populations treated in specialized centres for atrial fibrillation [31-35]. These approval studies show non-inferiority of NOACs as compared to the VKA agent warfarin, whereby patients under warfarin treatment spent on average (median) 65% of the follow-up time within the therapeutic range of INR 2–3 [35]. Owing to important differences in study design and a lack of head-to-head trials, whether or not the different NOAC agents are equivalent with regards to efficacy and safety has not been verified yet [36-40]. Data on the effectiveness of the agents (i.e. the extent to which the agents achieve their intended effect in the usual clinical setting) are derived from observational studies, not from randomized controlled trials, and often lack information on the TTR of patients under VKA treatment [41-47]. So, it remains unclear if these studies compared NOAC performance



to high or low quality VKA treatments. The validity of these comparisons is therefore limited. As far as the NOAC agent dabigatran is concerned, advantages over warfarin were only seen in study centres where TTR was less than 72% [48].

By contrast, there are also examples of high quality TTR control in daily practice. Previous reports from Sweden and the Netherlands documented TTR benchmarks as high as 76% and 81%, respectively [49-51]. Moreover, a sub-analysis of the ROCKET AF trial revealed global geographic region as being the strongest predictor of patients' individual TTR independent of patients' characteristics such as age and comorbidities [52]. This finding is likely to reflect different structures of care and support systems to manage warfarin and different regional barriers to frequent INR testing and warfarin dose changes. Under daily practice conditions – outside of clinical trials – local differences also include the use of VKA agents other than warfarin (e.g. phenprocoumon, fluindione, acenocoumarol) that differ considerably regarding their half-lives, further affecting the comparability of local settings [18,53,54].

Therefore, it seems unjustified to extrapolate findings made under study conditions or in foreign healthcare settings and to define a one-size-fits-all decision on first-line anticoagulant agents and ideal provision of care services without discussing the current standard of TTR control in specific care settings.

It is the aim of our study to contribute data on TTR control achieved in Swiss primary care practices to the discussion. As in many other countries, long-term anticoagulant therapy in Switzerland is mainly a task of general practitioners (GPs) [55]. Available VKA agents are phenprocoumon and acenocoumarol. Most frequently, phenprocoumon is used. INR monitoring is usually performed using a point-of-care device in order to adjust VKA dosage prescription during the same consultation if necessary. To date, the average TTR achieved in this setting is unknown, and it is unclear whether the patient populations of the RCTs are representative of Swiss primary care patients. We aim:

- 1) to evaluate the stability of anticoagulant treatment in Swiss primary care expressed as patients' average TTR of INR 2–3 as compared to the TTR levels achieved in the warfarin



arms of NOAC approval studies, RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48 [31-34];

- 2) to evaluate the characteristics of patients who receive long-term anticoagulant treatment with VKAs for ≥ 6 months in Swiss primary care;
- 3) to compare these characteristics to baseline characteristics of intention-to-treat (ITT) populations included in the abovementioned RCTs; and
- 4) to assess the impact of patient characteristics known to affect anticoagulation control with VKA measured by TTR;

Material and Methods

In this retrospective longitudinal study, we calculated the TTR of Swiss primary care patients receiving long-term anticoagulant treatment with VKAs for ≥ 6 months without interruption based on recorded results of INR tests according to Rosendaal's formula [56]. The combined ITT population included in the NOAC approval studies RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48 served as a comparator to our study population. We will subsequently refer to this population as the NOAC RCT population.

FIRE database

Eligible patients were identified from the primary care research database FIRE (Family medicine ICPC Research using Electronic medical records) receiving long-term anticoagulant treatment with VKAs for ≥ 6 months. The FIRE database is the core of an ongoing health services research project at the Institute of Primary Care at the University and University Hospital of Zurich, Switzerland. Details about the project, the data structure and the validation of the database were reported previously [57,58]. In short, the database established in 2009 contains information on all physician-patient contacts in participating primary care practices around Switzerland. Data are extracted from routinely used electronic medical records, fully anonymized and aggregated by individual consultation dates and

randomly generated, de-identifiable but unique patient ID numbers. The dataset covers patients' age, sex, reasons for encounter according to the ICPC-2 classification (International Classification of Primary Care 2) [59], vital signs, laboratory test results as well as type and dosage of prescribed medication according to Anatomical Therapeutic Chemical/Defined Daily Dose Classification (ATC/DDD) coding established by the WHO [60]. According to current Swiss law on human research retrospective analysis of anonymously collected medical routine data requires no approval by regional ethics committees [61].

Patient population

All patients with INR tests recorded between May 2009 and January 2015 were eligible and included based on the following criteria:

- prescribed VKA treatment for at least 6 months (this criterion would exclude patients with VKA treatment due to a first event of deep vein thrombosis and time-limited risk of thromboembolic disease)
- no prescription of heparin agents during VKA treatment period (this criterion would exclude patients with periprocedural interruption of VKA treatment and heparin bridging).

Patients' baseline characteristics were directly obtained from the FIRE database or derived from the available dataset as follows: Indication for anticoagulant treatment was derived from the ICPC-2 codes assigned to the patient during VKA treatment; Presence of concomitant chronic conditions were derived both from ICPC-2 codes and pharmaceutical cost groups based on ATC/DDD coding according to the established algorithms of O'Halloran et al. and Lamers et al., respectively [62,63]. This approach has previously been validated for the FIRE database [58,64]; All drugs prescribed for at least 6 months were considered to be long-term medication and counted as concomitant drugs; CHADS₂-Score of stroke risk in patients with atrial fibrillation according to ICPC-2 coding was calculated according to Gage, et al. [65]. We used the CHADS₂-Score instead of the CHA₂DS₂-VASc-Score for comparison reasons, because the NOAC approval studies exclusively reported the CHADS₂-Score. Creatinine



clearance in ml/min was calculated based on serum creatinine values according to the Cockcroft-Gault equation [66]. Bleeding events were not registered in the database.

Comparative studies

Baseline characteristics of the NOAC RCT population were extracted from the datasets of the RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48 studies published in medical literature [31-35].

Outcome definitions

We defined good anticoagulation control as TTR >70%, moderate control as TTR 61–70%, poor control as TTR 40–60% and ineffective control as TTR <40% based on guideline recommendations and current literature [38,67-74].

Statistics

Data are presented as frequencies and percentages, mean and standard deviation (SD) or median and interquartile range (IQR), where appropriate. If not indicated otherwise, all percentages refer to the total number of included patients. First, correlation of TTR and age, sex, overall number of chronic conditions and drugs taken, hypertension, diabetes, congestive heart failure, creatinine clearance, CHADS₂-scoring, length of observation (years), number of physician-patient contacts and number of INR tests was assessed using univariable linear regression models. Results are presented as coefficients, 95% confidence intervals (CI) and p-values. A p-value <0.1 was considered as statistically significant. In a second step, all variables showing a significant impact on TTR in univariable analysis were included in a multivariable linear regression model. Subsequently, robustness of the results was tested by adding GPs as random variable to the model (mixed model) in order to adjust for clustering effects. Then, a p-value <0.05 was considered as statistically significant. All



statistical analyses were done in R (version 3.0.2, The R Foundation for Statistical Computing, Vienna, Austria).

Results

Consultation data of 670 patients with INR tests recorded between May 2009 and January 2015 were eligible. Of these, 256 patients received VKA treatment for less than 6 months and were thus excluded. Another 199 patients were excluded because of periprocedural interruption of VKA treatment and heparin bridging (Flowchart in Fig. 1). 215 patients treated by 12 physicians fulfilled the inclusion criteria and were included in the analysis. Patient characteristics are summarized in Table 1. The NOAC RCT population included 71'683 patients. Of these, 29'272 were allocated to warfarin treatment.

Our patients were similar to the ITT population included in the NOAC RCTs in terms of length of observation (both median 2.2 y), rate of concomitant hypertension (87.9% vs. 88%) and CHADS₂-scoring (median 2.7 vs. 2.6). Differences were found in terms of sex, age, rate of concomitant diabetes mellitus and congestive heart failure, creatinine clearance and number of INR tests per year and patient (Table 1). In our study population, more patients were female (50.7% vs. 37.5%) and aged 75 years or older (67.9% vs. 38%). The proportion of patients with concomitant diagnosis of diabetes mellitus was lower than in the NOAC approval studies (18.1% vs. 31%), whereas the proportion of patients with congestive heart failure was higher (61.4% vs. 46.5%). In sum, more patients in our study showed a creatinine clearance of ≥ 50 ml/min (84.5% [n=115/136] vs. 81.5%), but unlike in the NOAC approval studies, also two (1.5%) patients with creatinine clearance ≤ 30 ml/min were included. The median number of GP encounters within our study population was 14.5 times per year, and INR was tested every 6 weeks (median 8 tests per year). The NOAC approval studies requested at least monthly follow-up contacts and INR tests in patients receiving warfarin – that is a minimum of 12 tests per year.

Number of chronic conditions other than those leading to an indication for anticoagulant treatment, number of additional drugs taken and liver function parameters (aspartate transferase, AST; alanine transferase, ALT) of the NOAC RCT population have not been publicly published. In our study population, the mean number of concomitant chronic conditions was 5.3 (SD 2.3). Apart from VKA, patients took 7 (SD 4.2) concomitant drugs. Mean values of both AST and ALT were within the reference ranges as specified by the International Federation of Clinical Chemistry and Laboratory Medicine [75], but one patient ($n=1/101$, 1%) showed values >2 times the upper limit of normal (ULN). Such values constituted an exclusion criterion in the RELY, ARISTOTLE and ENGAGE-AF-TIMI 48 trials [76-78]. No patient showed values >3 times ULN (exclusion criterion in the ROCKET-AF trial [34]).

Time in therapeutic range (TTR)

Individual median INR in our study population was 2.4. Patients spent median 75% of treatment time within the therapeutic range of INR 2–3. Median TTR in the warfarin arm of the NOAC RCTs was 65% (Table 2). In our study, 60.9% of patients reached or exceeded this threshold ($TTR \geq 65\%$). The majority of our patients showed good (55.8% with $TTR > 70\%$) or moderate (9.8% with $TTR 61–70\%$) anticoagulation control. Poor and ineffective control was found in 20.9% and 13.5%, respectively. The median treatment time in a subtherapeutic INR range ($INR < 2$) was 10.1% (IQR 1.8–29.6%) and the median treatment time above the therapeutic range ($INR > 3$) was 5.5% (IQR 0–17.2%).

Univariable linear regression analysis demonstrated significant associations between lower TTR and patients' age, sex, number of concomitant chronic conditions and diagnosis of congestive heart failure, and significant associations between higher TTR and length of observation and number of INR tests (Table 3). In the subsequently performed multivariable regression analysis, sex remained a significant predictor of TTR and was significantly modified by age ($p=0.0059$ for the interaction term $sex*age$). This result remained unchanged when controlled for a cluster effect originating from GPs. Age was not an independent



predictor of TTR, but a significant interaction between age and sex was found. A cluster effect was not present (Table 4).

Discussion

In this study, we examined the quality of anticoagulant treatment with VKA in Swiss primary care patients, measured by individual TTR. It is the first study of this kind in Switzerland and showed a remarkably high level of TTR control. Median TTR was 75% exceeding not only the median TTR level achieved in the NOAC RCTs but also TTR levels reported from daily practice settings in other Western countries, and is comparable to the data on anticoagulation self-management in Switzerland [79]. This finding ranks Switzerland with the best performing countries, Sweden and the Netherlands, which had previously reported TTR benchmarks of 76% and 81% [49-51].

Previous estimations of the quality of VKA treatment control in Switzerland did not forecast our finding. In the absence of real life data, these estimations were made based on regional analyses of NOAC RCTs. They suggested that TTR levels achieved in Swiss patients would be of minor quality. In the RE-LY trial, for instance, Swiss study centres showed a mean centre TTR of 68% [48]. In the ROCKET-AF trial, mean individual TTR of Swiss patients was below the average baseline TTR of Western Europe (63.2%) [52]. The impact of such estimations must not be underestimated. According to current European guidelines, patients with a TTR below 70% should receive NOAC instead of VKA [38]. Based on the abovementioned estimations of TTR levels achieved in the Swiss healthcare setting, one could conclude that the majority of Swiss patients under VKA treatment had to be switched to NOAC and patients should generally be started on NOAC in order to avoid a few promising but strenuous VKA therapy initiation [71]. Not only would large quantities of therapy changes challenge patients and clinicians, but the mass of new NOAC prescription would also have relevant economic influence on the country's obligatory health insurance system covering anticoagulant treatment. It has been shown that NOACs can be cost-effective in specific



settings despite higher pharmaceutical costs, because overall costs for anticoagulation related outpatient visits and hospitalizations were reduced compared to warfarin treatment [80-84]. However, just like clinical outcomes, also cost-efficiency estimations have been demonstrated to depend on TTR levels achieved in the VKA group [85,86].

Our findings, now, reduce concerns about the magnitude of the patient population requiring therapy changes by suggesting that the majority of Swiss patients maintain stable TTR levels and would not require therapy changes. Moreover, regression analysis indicated that TTR was independent of a wide range of patient characteristics. We conclude that all GPs were apparently able to control TTR irrespective of confounding influences.

Strength and limitations

Of course, it needs to be acknowledged that our study sample was small compared to the overall number of patients included in the NOAC RCTs or in foreign observation registries [5,8,24]. One might further argue that there are a number of potential confounders impacting on TTR that we did not include in our regression models. In response to these claims, it is to note that the strength of our study is not only the use of local data, but also setting-specific data. Two aspects are to note:

- 1) All figures must be seen in proportion to the limited availability of regional data. Numbers of Swiss patients recruited in the RE-LY and ARISTOTLE trials are not publicly published, but it is known that TTR information on Swiss patients in the ROCKET-AF study were derived from only four Swiss patients [87]. In the ENGAGE-AF-TIMI 48 trial, zero Swiss patients received warfarin [88]. In comparison, we present results from 215 patients.
- 2) It was not the aim of this study to newly identify all potentially imaginable determinants of TTR control. We assessed the impact of those baseline characteristics in our dataset that are known to affect anticoagulation control in order to control for potential confounders.



Thus, our results should not be generalized to other health care settings nor be understood in a way that TTR control is always independent of patient characteristics. It is widely verified that patient characteristics such as concomitant diseases and female sex – also significant in our study – can act as significant predictors of TTR [2,8,12,51,71]. Explanations for these observations are, however, scarce. It is likely that some of the previously reported associations of TTR and patient characteristics are random effects due to multiple testing in very large data samples. On the other hand, it may also be well assumed that the previously observed effects actually reflect underlying differences of patients' health literacy, self-management resources, adherence to medical advice or access to medical care, in brief sociodemographic and infrastructural features of the healthcare setting [89].

The results of our mixed models regression analysis indicate that features of the Swiss primary care setting, other than number of consultations and INR tests, might overrule the effect of patient characteristics on TTR control and ensure stable TTR maintenance. For instance, the point-of-care testing in GP practices is an important feature that is known to influence TTR [90,91]. It will be a task of future research to examine this hypothesis with adequate methods.

It was the aim of our study to evaluate TTR control in the circumscribed setting of Swiss primary care and call one-size-fits-all recommendations of first-line anticoagulant treatment into question. Indeed, our results highlight the importance of local and setting-specific TTR assessments by demonstrating that real-life TTR outcomes in individual health care settings may deviate from expected values derived from RCTs or observation studies in foreign health care systems. It is important to note that our patients achieved better TTR results than the NOAC control group population, even though our patients were remarkably older than the NOAC ITT population and presented a lot of concomitant chronic diseases and polypharmacy. This raises concerns about the «gold standard» of VKA treatment that served as a reference in the NOAC RCTs and should be taken into account when deriving practice guidelines from RCT results. Initial observations indicating that patients enrolled in NOAC RCTs are only partly representative of patients with atrial fibrillation in clinical practice were



made in Korea [92]. Our study confirms these findings now within a European context, but unlike the Korean study, we found that when TTR is considered, fewer patients than expected would require NOAC therapy instead of VKA.

Of course, TTR should not be the only basis of decision-making. Bleeding events are another reason for switching to NOACs, but were out of scope of this study. None of the observed patients stopped VKA treatment because of bleeding events, but information on patients was limited to GPs medical record entries. Thus, occurrence of bleeding events leading to consultation of other healthcare providers cannot be ruled out entirely. Bleeding prevalence in Swiss VKA patients should be examined in a next step.

The burden of treatment should also be considered when selecting anticoagulant agents, and in many situations the ease of use will speak in favor of NOACs. Nevertheless, it must be acknowledged that periodical INR monitoring required under VKA treatment imposes not necessarily a burden for patients and primary physicians. A recent study suggested that it could also enhance patient-physician relation and therapy adherence and offer opportunities for the physician to provide additional care to patients, such as adjusting the dosage of antihypertensive drugs, giving smoking cessation advice or treating high cholesterol [93]. Our findings now show that concomitant comprehensive care for other conditions does not impair physicians' resources in controlling INR and ensuring high quality TTR control. This is of particular relevance for daily practice in primary care worldwide, given the high prevalence of multimorbidity in primary care patients [94].

As long as published data on NOAC use in elderly, multimorbid patient populations is scarce, general recommendations of NOACs as first-line treatment in such patients should be taken with caution. In the meantime, physicians should instead tailor anticoagulation management according to the individual needs of their patients with regard to the heterogeneity, age, multimorbidity and risk profile of patients in primary care settings. Our findings show that high quality TTR can be achieved even in such vulnerable patients.



Conclusion

Choice of anticoagulant agents is a complex medical decision and should be taken in comprehensive view of patients' individual risk-benefit profile. Practitioners should consider that the non-inferiority of NOACs has been proven in RCTs which enrolled patients who are only partly representative of patients in primary care, particularly in terms of TTR maintenance when receiving VKA treatment. The observed majority of our patients would not require an immediate switch to NOACs due to low-quality TTR. Further research is needed in order to identify specific features of care management that are associated with these outcomes, since most patients' characteristics were insignificant predictors of TTR.

Authors contributions

S.D., O.S., D.M. and B.G. developed the study protocol. S.D. and F.V. extracted and analyzed data. S.D. drafted the manuscript. All authors read and approved the final manuscript.



References:

1. Mitchell SA, Simon TA, Raza S et al. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis. *Clinical and applied thrombosis/hemostasis* : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2013; 19: 619-631.
2. Apostolakis S, Sullivan RM, Olshansky B et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAME-TT(2)R(2) score. *Chest* 2013; 144: 1555-1563.
3. Aslan O, Yaylali YT, Yildirim S et al. Dabigatran Versus Warfarin in Atrial Fibrillation: Multicenter Experience in Turkey. *Clinical and applied thrombosis/hemostasis* : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2014; DOI: 10.1177/1076029614546327.
4. Baker WL, Cios DA, Sander SD et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. *Journal of managed care pharmacy* : JMCP 2009; 15: 244-252.
5. Bertomeu-Gonzalez V, Anguita M, Moreno-Arribas J et al. Quality of Anticoagulation With Vitamin K Antagonists. *Clinical cardiology* 2015; 38: 357-364.
6. Currie CJ, McEwan P, Emmas C et al. Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population. *Current medical research and opinion* 2005; 21: 1905-1913.
7. Dlott JS, George RA, Huang X et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. *Circulation* 2014; 129: 1407-1414.



8. Macedo AF, Bell J, McCarron C et al. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink. *Thrombosis research* 2015; 136: 250-260.

9. Reynolds MW, Fahrbach K, Hauch O et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. *Chest* 2004; 126: 1938-1945.

10. Rose AJ, Hylek EM, Ozonoff A et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). *Journal of thrombosis and haemostasis* : JTH 2010; 8: 2182-2191.

11. Shen AY, Yao JF, Brar SS et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. *J Am Coll Cardiol* 2007; 50: 309-315.

12. van Walraven C, Jennings A, Oake N et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. *Chest* 2006; 129: 1155-1166.

13. Wan Y, Heneghan C, Perera R et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. *Circulation Cardiovascular quality and outcomes* 2008; 1: 84-91.

14. Wutzler A, von Ulmenstein S, Attanasio P et al. Treatment of Nonagenarians With Atrial Fibrillation: Insights From the Berlin Atrial Fibrillation (BAF) Registry. *Journal of the American Medical Directors Association* 2015; pii: S1525-8610(15)00379-5. doi: 10.1016/j.jamda.2015.05.012. [Epub ahead of print].

15. Ansell J, Hollowell J, Pengo V et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). *Journal of thrombosis and thrombolysis* 2007; 23: 83-91.

16. Chamberlain MA, Sageser NA, Ruiz D. Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic. *The Journal of the American Board of Family Practice* / American Board of Family Practice 2001; 14: 16-21.
17. Cios DA, Baker WL, Sander SD et al. Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis. *American journal of health-system pharmacy* : AJHP : official journal of the American Society of Health-System Pharmacists 2009; 66: 916-925.
18. De Caterina R, Husted S, Wallentin L et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. *Thrombosis and haemostasis* 2013; 110: 1087-1107.
19. Nichol MB, Knight TK, Dow T et al. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. *The Annals of pharmacotherapy* 2008; 42: 62-70.
20. Pengo V, Pegoraro C, Cucchini U et al. Worldwide management of oral anticoagulant therapy: the ISAM study. *Journal of thrombosis and thrombolysis* 2006; 21: 73-77.
21. Wilson SJ, Wells PS, Kovacs MJ et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. *CMAJ : Canadian Medical Association journal* = journal de l'Association medicale canadienne 2003; 169: 293-298.
22. Witt DM, Sadler MA, Shanahan RL et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. *Chest* 2005; 127: 1515-1522.



23. Cotte FE, Benhaddi H, Duprat-Lomon I et al. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. *Clinical therapeutics* 2014; 36: 1160-1168.
24. Pokorney SD, Simon DN, Thomas L et al. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. *American heart journal* 2015; 170: 141-148 e141.
25. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. *Lancet* 1996; 348: 423-428.
26. Poli D, Antonucci E, Testa S et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. *Circulation* 2011; 124: 824-829.
27. Prandoni P, Noventa F, Ghirarduzzi A et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. *Haematologica* 2007; 92: 199-205.
28. Sudlow M, Thomson R, Thwaites B et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. *The Lancet* 1998; 352: 1167-1171.
29. Garcia-Alamino JM, Ward AM, Alonso-Coello P et al. Self-monitoring and self-management of oral anticoagulation. *The Cochrane database of systematic reviews* 2010: CD003839.
30. Bauer KA. Pros and cons of new oral anticoagulants. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program* 2013; 2013: 464-470.



31. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. *The New England journal of medicine* 2009; 361: 1139-1151.
32. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. *The New England journal of medicine* 2013; 369: 2093-2104.
33. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. *The New England journal of medicine* 2011; 365: 981-992.
34. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *The New England journal of medicine* 2011; 365: 883-891.
35. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014; 383: 955-962.
36. Lip GY, Larsen TB, Skjoth F et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. *J Am Coll Cardiol* 2012; 60: 738-746.
37. Palareti G. Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding. *Seminars in hematology* 2014; 51: 102-111.
38. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* 2012; 14: 1385-1413.



39. Tichelaar V, Meijer K. Determinants and consequences of differences in quality of anticoagulation therapy with vitamin K antagonists. *Thrombosis research* 2015; 136: 182-184.
40. Sharma M, Cornelius VR, Patel JP et al. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. *Circulation* 2015; 132: 194-204.
41. Larsen TB, Rasmussen LH, Gorst-Rasmussen A et al. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran or warfarin. *The American journal of medicine* 2014; 127: 329-336 e324.
42. Larsen TB, Rasmussen LH, Skjoth F et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. *J Am Coll Cardiol* 2013; 61: 2264-2273.
43. Schneeweiss S, Huybrechts K, J G. Interpreting the quality of health care database studies on the comparative effectiveness of oral anticoagulants in routine care. *Comparative Effectiveness Research* 2013: 33-41.
44. Sipahi I, Celik S, Akyol A. Dabigatran's 'real-world' data about risk of myocardial infarction and gastrointestinal bleeding contradicts with randomized trials. *J Am Coll Cardiol* 2013; 62: 945-946.
45. Sorensen R, Gislason G, Torp-Pedersen C et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. *BMJ open* 2013; 3.
46. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. *The New England journal of medicine* 2013; 368: 1272-1274.



47. Graham DJ, Reichman ME, Wernecke M et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. *Circulation* 2015; 131: 157-164.

48. Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. *Lancet* 2010; 376: 975-983.

49. Wieloch M, Sjalander A, Frykman V et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. *European heart journal* 2011; 32: 2282-2289.

50. Bjorck F, Sanden P, Renlund H et al. Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden. *Thrombosis research* 2015; 136: 216-220.

51. Kooistra HAM, Veeger NJGM, Khorsand N et al. Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients. *Thrombosis and haemostasis* 2015; 113: 881-890.

52. Singer DE, Hellkamp AS, Piccini JP et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. *Journal of the American Heart Association* 2013; 2: e000067.

53. Jensen CF, Christensen TD, Maegaard M et al. Quality of oral anticoagulant therapy in patients who perform self management: warfarin versus phenprocoumon. *Journal of thrombosis and thrombolysis* 2009; 28: 276-281.

54. Le Heuzey JY, Ammentorp B, Darius H et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF Registry. *Thrombosis and haemostasis* 2014; 111: 833-841.



55. Streit S, Roberts R, Burman RA et al. Anticoagulation in primary care – a cross sectional study in 14 heterogeneous countries. *Cardiovascular Medicine* 2013; 16: 209-302.
56. Rosendaal FR, Cannegieter SC, van der Meer FJ et al. A method to determine the optimal intensity of oral anticoagulant therapy. *Thrombosis and haemostasis* 1993; 69: 236-239.
57. Chmiel C, Bhend H, Senn O et al. The FIRE project: a milestone for research in primary care in Switzerland. *Swiss medical weekly* 2011; 140: w13142.
58. Zellweger U, Bopp M, Holzer BM et al. Prevalence of chronic medical conditions in Switzerland: exploring estimates validity by comparing complementary data sources. *BMC public health* 2014; 14: 1157.
59. WONCA. (World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians): ICPC-2-R: International Classification of Primary Care. *Oxford University Press* 2005; .
60. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. In. 15th ed. Oslo; 2011.
61. The federal council of the Swiss confederation: Federal Act on Research involving Human Beings (Human Research Act, HRA) of 30 September 2011 (Status as of 1 January 2014). <https://www.admin.ch/opc/en/classified-compilation/20061313/index.html> ; Accessed 14 December 2015.
62. Lamers LM, van Vliet RCJA. The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. *Health Policy* 2004; 68: 113-121.



63. O'Halloran J, Miller GC, Britt H. Defining chronic conditions for primary care with ICPC-2. *Family Practice* 2004; 21: 381-386.
64. Rizza A, Kaplan V, Senn O et al. Age- and gender-related prevalence of multimorbidity in primary care: the Swiss FIRE project. *BMC family practice* 2012; 13: 113.
65. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA : the journal of the American Medical Association* 2001; 285: 2864-2870.
66. Cockcroft DW, Cockcroft DW, Gault H. Prediction of Creatinine Clearance from Serum Creatinine. *Nephron* 1976; 16: 31-41.
67. Veeger NJ, Piersma-Wichers M, Tijssen JG et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. *British journal of haematology* 2005; 128: 513-519.
68. White HD, Gruber M, Feyzi J et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. *Archives of internal medicine* 2007; 167: 239-245.
69. Connolly SJ, Pogue J, Eikelboom J et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. *Circulation* 2008; 118: 2029-2037.
70. Morgan CL, McEwan P, Tukiendorf A et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. *Thrombosis research* 2009; 124: 37-41.



71. Roldan V, Marin F. The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. *Thrombosis and haemostasis* 2015; 113: 671-673.

72. De Caterina R, Husted S, Wallentin L et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. *J Am Coll Cardiol* 2012; 59: 1413-1425.

73. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol* 2014; .

74. National Institute for Health and Care Excellence (NICE): Atrial fibrillation: the management of atrial fibrillation. (Clinical guideline 180). 2014;
<http://www.nice.org.uk/guidance/cg180/evidence/cg180-atrial-fibrillation-update-full-guideline3>
 ; Accessed 09 July 2015.

75. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): Reference Materials. <http://www.ifcc.org/ifcc-scientific-division/reference-materials/> ; Accessed 21 July 2015.

76. Ezekowitz MD, Connolly S, Parekh A et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. *American heart journal* 2009; 157: 805-810, 810.e801-802.

77. Lopes RD, Alexander JH, Al-Khatib SM et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. *American heart journal* 2010; 159: 331-339.

78. Ruff CT, Giugliano RP, Antman EM et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective



aNticoagulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In

Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). *American heart journal* 2010; 160: 635-641.


79. Nagler M, Bachmann LM, Schmid P et al. Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study. *PloS one* 2014; 9: e95761.
80. Laliberte F, Cloutier M, Crivera C et al. Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users. *Advances in therapy* 2015; .
81. Seaman CD, Smith KJ, Ragni MV. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective. *Thrombosis research* 2013; 132: 647-651.
82. Lanitis T, Kongnakorn T, Jacobson L et al. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation. *Thrombosis research* 2014; 134: 278-287.
83. Rognoni C, Marchetti M, Quaglini S et al. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. *Journal of thrombosis and thrombolysis* 2015; 39: 149-154.
84. Pletscher M, Plessow R, Eichler K et al. Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. *Swiss medical weekly* 2013; 143: w13732.
85. Amin A, Deitelzweig S, Jing Y et al. Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. *Journal of thrombosis and thrombolysis* 2014; 38: 150-159.



86. You JH. Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis. *Journal of general internal medicine* 2014; 29: 438-446.
87. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET-AF): Trial record NCT00403767. <https://clinicaltrials.gov/ct2/show/NCT00403767?term=ROCKET-AF&rank=1> ; Accessed 31 July 2015.
88. Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation (EngageAFTIMI48): Trial Record NCT00781391. https://clinicaltrials.gov/ct2/show/results/NCT00781391?term=ENGAGE+Edoxaban&rank=1&how_locs=Y§=X0156#part ; Accessed 14 August 2015.
89. Amin A, Marrs JC. Direct Oral Anticoagulants for the Management of Thromboembolic Disorders: The Importance of Adherence and Persistence in Achieving Beneficial Outcomes. *Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis* 2015; .
90. Okuyama Y, Matsuo M, Matsuo H et al. Introduction of point-of-care testing in Japanese outpatient clinics is associated with improvement in time in therapeutic range in anticoagulant-treated patients. *Circulation journal* : official journal of the Japanese Circulation Society 2014; 78: 1342-1348.
91. Lokkegaard T, Pedersen TH, Lind B et al. Good quality of oral anticoagulation treatment in general practice using international normalised ratio point of care testing. *Dan Med J* 2015; 62.
92. Yoon CH, Park YK, Kim SJ et al. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke. *Stroke; a journal of cerebral circulation* 2014; 45: 2983-2988.



93. Streit S, Kaplan V, Busato A et al. General Practitioners' vitamin K antagonist monitoring is associated with better blood pressure control in patients with hypertension--a cross-sectional database study. *BMC cardiovascular disorders* 2015; 15: 47.
94. Boeckxstaens P, Peersman W, Goubin G et al. A practice-based analysis of combinations of diseases in patients aged 65 or older in primary care. *BMC family practice* 2014; 15: 159.

Fig. 1: Flow chart of study sample selection – patients with VKA therapy

**Tab. 1: Baseline characteristics of included patients in comparison to the intention-to-treat population of the NOAC approval studies**

Baseline characteristics				Included patients (n=215)		Combined ITT population included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials (n=71'683)‡	
Gender							
Male				106	49.3%		62.5%
Female				109	50.7%		37.5%
Age (y)							
mean, SD				77.2	11.8	71.6	
Patients ≥75 y				146	67.9%		38%
Indication for anticoagulant treatment							
Non-valvular atrial fibrillation				104	48.4%	71'683	100%
Pulmonary embolism				15	7.0%	0	0%
Recurrent deep vein thrombosis				11	5.1%	0	0%
Missing information				82	38.1%	0	0%
Chronic conditions							
Patients with ≥1 chronic condition				214	99.5%	NA	NA
Number of chronic conditions (mean, SD)				5.3	2.3	NA	NA
Hypertension (n,%)				189	87.9%		88%
Diabetes mellitus (n,%)				39	18.1%		31%
Congestive heart failure (n,%)				132	61.4%		46.5%
Concomitant long-term medication							
Patients with ≥1 concomitant drugs				207	96.3%	NA	NA
Number of concomitant drugs (mean, SD)				7	4.2	NA	NA
Observation period (y)							
median, IQR				2.2	1.5-4.1	2.2	
Number of contacts per year							
median, IQR				14.5	9.4-23.5	NA	NA
Number of INR tests per year							
median, IQR				8.0	5.2-11.8	12 (at least 1/month)	
CHAD₂-Score of stroke risk*							
mean, SD				2.7	1.2	2.6	1.0
Score (n,%)							
0-1				9	8.7%		17%
2				31	29.8%		34%
3-6				64	61.5%		49%
Creatinine clearance (ml/min)**							
GFR (mean, SD)				73.4	22.9	NA	NA
≥50 ml/min				115	84.6%		81%
<50 ml/min (n,%)				21	15.4%		19%
≤30 ml/min (n,%)				2	1.5%	exclusion criterion	
Liver function enzymes (U/l)***							
AST (mean, SD)				20.4	7.7	NA	NA
ALT (mean, SD)				19.3	14.3	NA	NA
>2 ULN (n,%)				1	1.0%	exclusion criterion	

* data calculated from n=104 (48.4%) of included patients with ICPC diagnosis of Atrial Fibrillation

** data available from n=136 (63.3%) of included patients

*** data available from n=101 (47.0%) of included patients

‡ data calculated from published data in [33];

ITT: intention-to-treat; SD: standard deviation; IQR: interquartile range; INR: international normalized ratio; GFR: glomerular filtration rate; AST: aspartate transferase; ALT: alanine transferase; ULN: upper limit of normal



Tab. 2: INR and Time in therapeutic range (TTR) achieved in the study population in comparison to the intention-to-treat population of the NOAC approval studies

	Study population (n=215)		Combined ITT population receiving Warfarin in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials (n=29'272)‡	
Individual median INR (IQR)	2.4	(2.2 – 2.6)	NA	NA
Individual median TTR (IQR)	75%	(53% – 89%)	65%	(51% – 76%)

‡ data from [33]

INR: international normalized ratio; TTR: time in therapeutic range; IQR: interquartile range

Tab. 3: Coefficients and 95% CIs from univariable regression models

Variable	Coefficient	CI 95%	p-value‡
Age	-0.005	-0.008 – -0.002	0.0004 *
Sex (female)	-0.138	-0.204 – -0.073	0.0001 *
Number of chronic conditions	-0.016	-0.031 – -0.001	0.0326 *
Number of concomitant drugs	-0.007	-0.015 – 0.001	0.1015
Hypertension	-0.083	-0.189 – 0.023	0.1265
Diabetes mellitus	-0.056	-0.144 – 0.033	0.2177
Congestive heart failure	-0.072	-0.142 – -0.003	0.0426 *
Glomerular filtration rate (ml/min)	0.000	-0.001 – 0.001	0.9784
CHAD ₂ -Score of stroke risk	-0.010	-0.065 – 0.046	0.7314
Length of observation (years)	0.028	0.005 – 0.050	0.0155 *
Number of consultations	0.000	-0.001 – 0.001	0.5543
Number of INR tests	0.002	0.000 – 0.004	0.0629 *

‡significance level p<0.1, significant values are marked with an asterisk

**Tab. 4: Coefficients and 95% CIs from a multivariable regression model (mixed model):**

TTR=age*sex+number of chronic conditions+congestive heart failure+length of observation+number of INR tests with GP as random variable

	Coefficient	CI 95%	p-value [‡]
Age	-4.3E-05	-0.004 – 0.004	0.9824
Sex (female)	-0.105	-0.173 – -0.038	0.0023 *
Age*Sex (female)	-0.009	-0.015 – -0.003	0.0059 *
Number of chronic conditions	-0.013	-0.029 – 0.003	0.1099
Congestive heart failure	-0.027	-0.102 – 0.048	0.4862
Length of observation (years)	0.012	-0.018 – 0.043	0.4293
Number of INR tests	0.002	-0.001 – 0.004	0.2252

[‡]significance level $p < 0.05$, significant values are marked with an asterisk